# AZD9793

Source: https://onco.cc/drugs/azd9793/  
OnCo record `azd9793` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.

## Summary

AZD9793 is a T-cell engager developed by AstraZeneca. Its target is Glypican-3 (the sponsor names GPC3). The sponsor states: AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma. ClinicalTrials.gov describes the intervention as: T cell-engaging antibody that targets GPC3 on tumour cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hepatocellular carcinoma. The largest, NCT06795022, plans to enrol 304 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: T-cell engager
- Mechanism: AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma.

## Sources

- ClinicalTrials.gov: trials of AZD9793: https://clinicaltrials.gov/search?intr=AZD9793

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- targets: [Glypican-3](https://onco.cc/targets/gpc3/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours](https://onco.cc/trials/nct06795022/)

---
JSON: https://onco.cc/api/v1/entities/azd9793.json